Advances in biomarkers of resistance to KRAS mutation-targeted inhibitors
Abstract KRAS mutations represent the most common driver genetic alterations in multiple malignant tumors, particularly exerting well-defined oncogenic driver roles in non-small cell lung cancer, colorectal cancer, and pancreatic ductal adenocarcinoma. The recent success of KRAS G12C mutation-specif...
Tallennettuna:
| Päätekijät: | , , , |
|---|---|
| Aineistotyyppi: | Artigo |
| Kieli: | Inglês |
| Julkaistu: |
Springer
2025-10-01
|
| Sarja: | Discover Oncology |
| Aiheet: | |
| Linkit: | https://doi.org/10.1007/s12672-025-03569-x |
| Tagit: |
Ei tageja, Lisää ensimmäinen tagi!
|